1. Scrip
  2. >>R&D

TG’s Follicular Lymphoma Data Suggest Umbralisib Could Succeed In PI3K Delta Class

 
• By Joseph Haas

Overall survival data from a follicular lymphoma cohort of its umbrella NHL study indicate umbralisib could match other PI3K delta inhibitors’ efficacy with better safety/tolerability profile.

Follicular lymphoma is one of mature B-cell neoplasm
TG Therapeutics hopes it can provide a safer, more tolerable follicular lymphoma therapy

Already preparing to file for approval of umbralisib in mantle cell lymphoma, TG Therapeutics Inc. now has overall survival data in follicular lymphoma patients that suggest the PI3K delta inhibitor could offer a better overall profile than other drugs in its class approved for third-line or later treatment.

The New York-based biotech revealed on 28 October that umbralisib monotherapy met the primary endpoint of overall response in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D